Introduction {#s1}
============

Hepatocellular carcinoma is one of the most common types of cancer, with nearly 600,000 newly-diagnosed cases of patients with hepatocellular carcinoma ([@B1]--[@B3]).

Although great advances in the therapeutic approaches have been achieved in the past decades, the prognosis of patients with hepatocellular carcinoma remains dismal, with five-year survival rates less than 20% ([@B4]). Most of patients diagnosed at advanced stage of hepatocellular carcinoma and high incidence of recurrence and metastasis after curative therapies may account for this poor prognosis ([@B5]). Therefore, exploring detailed mechanisms of pathogenesis of hepatocellular carcinoma and identifying promising diagnostic and prognostic biomarkers of hepatocellular carcinoma may be helpful for providing effective therapeutic targets and improving patients\' outcome. A hypothesis, namely competing endogenous RNA (ceRNA), that non-coding RNA (ncRNA), including long non-coding RNA (lncRNA), can cross-talk with messenger RNA (mRNA) by competitively binding to shared miRNAs was proposed by Salmena et al. ([@B6]). In recent years, a variety of studies regarding roles of competing endogenous RNA (ceRNA) regulatory network in human cancers have been launched and lots of attractive findings have been obtained. For example, Li et al. ([@B7]) identified prognostic signatures associated with long-term overall survival of thyroid cancer patients based on a competing endogenous RNA network; Wang et al. ([@B8]) found some prognostic markers for glioblastoma by ceRNA network analysis; Wang et al. ([@B9]) constructed a mRNA-miRNA-lncRNA competing endogenous RNA triple sub-network associated with prognosis of pancreatic cancer. However, current knowledge about ceRNA regulatory network in hepatocellular carcinoma remains extremely limited and need to be further probed. In this study, by employing "mRNA-miRNA-lncRNA" order pattern instead of "lncRNA-miRNA-mRNA" order pattern, we constructed a comprehensive ceRNA sub-network, in which all RNAs possess significant diagnostic and prognostic values for patients with hepatocellular carcinoma.

Materials and Methods {#s2}
=====================

GEPIA Database Analysis
-----------------------

GEPIA (Gene Expression Profiling Interactive Analysis, <http://gepia.cancer-pku.cn/detail.php>) is a newly developed interactive web server for analyzing the RNA sequencing expression data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) projects ([@B10]). GEPIA was employed to obtain the genes most associated with overall survival and disease-free survival of patients with hepatocellular carcinoma. Logrank *P* \< 0.05 was considered as statistically significant. GEPIA was also used to perform expression analysis and survival analysis of lncRNA. The expression correlation between potential mRNA-lncRNA pairs was also determined by GEPIA. For expression analysis, *P* \< 0.05 was considered as statistically significant. For correlation analysis, *R* \> 0.1 and *P* \< 0.05 were set as the criteria for identifying significant mRNA-lncRNA interactive pairs.

UALCAN Database Analysis
------------------------

mRNA expression slevels of three candidate genes (CELSR3, GPSM2, and CHEK1) in hepatocellular carcinoma were further detected using UALCAN database (<http://ualcan.path.uab.edu/index.html>), which is a comprehensive, user-friendly, and interactive web resource for analyzing cancer data ([@B11]). *P* \< 0.05 was considered as statistically significant.

Oncomine Database Analysis
--------------------------

Oncomine (<https://www.oncomine.org/>) is a cancer microarray database and an integrated data-mining platform ([@B12]). In this study, Oncomine was utilized to analyze mRNA expression of CELSR2, GPSM2, and CHEK1 in hepatocellular carcinoma by conducting a meta-analysis of datasets as we previously described ([@B13]). *P* \< 0.05 and \|fold change\| \> 1.5 were set as the thresholds for selecting included datasets.

HumanProteinAtlas Database Analysis
-----------------------------------

HumanProteinAtlas (<https://www.proteinatlas.org/>) is a Swedish-based database, which was initiated in 2003 with the aim to map all the human proteins in cells, tissues and organs ([@B14]--[@B16]). CELSR2, GPSM2, and CHEK1 protein expression levels in hepatocellular carcinoma were assessed using HumanProteinAtlas database.

miRNet Database Analysis
------------------------

miRNet (<http://www.mirnet.ca/>), an easy-to-use online tool for miRNA-associated studies, was used to predict potential miRNAs binding to mRNAs ([@B17], [@B18]). Besides, it was also employed to predict potential lncRNAs binding to miRNAs. mRNA-miRNA and miRNA-lncRNA regulatory networks were subsequently established by Cytoscape software.

StarBase Database Analysis
--------------------------

starBase (<http://starbase.sysu.edu.cn/>) is an open-source database for investigating non-coding RNA interactions from CLIP-seq, degradome-seq and RNA-RNA interactome data ([@B19], [@B20]). starBase was introduced to perform expression correlation analysis for mRNA-miRNA and miRNA-lncRNA pairs in hepatocellular carcinoma. *R* \< −0.1 and *P* \< 0.05 were set as the criteria for identifying significant interactions. miRNA expression values in hepatocellular carcinoma were also determined using starBase. *P* \< 0.05 was considered as statistically significant. Besides, starBase was employed to predict potential lncRNAs binding to miRNAs.

Kaplan-Meier Plotter Analysis
-----------------------------

Kaplan-Meier plotter database is capable to assess the effect of miRNAs and genes on survival in 21 cancer types, including hepatocellular carcinoma ([@B21]). The prognostic values of potential miRNAs in hepatocellular carcinoma was evaluated using Kaplan-Meier plotter (<http://kmplot.com/analysis/>) as we previously described ([@B22], [@B23]). In brief, each miRNA of interest was first entered into this database. According to median expression value, all cases were classified into a low expression group and a high expression group. Subsequently, Kaplan-Meier survival plots were generated, and statistical indices containing hazard ratio (HR), 95% confidence interval (CI), logrank *P*-value were automatically calculated and directly displayed on the webpage. Logrank *P* \< 0.05 was considered as statistically significant.

Cell Culture and Clinical Tissues
---------------------------------

Human hepatocellular carcinoma cell lines hepG2 and LM3 and normal hepatic cell line HL7702 used in this study were kindly provided by the First Affiliated Hospital of Medical College, Zhejiang University (Hangzhou, China). All cell lines were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM; Gibco, 12430047) supplemented with 10% fetal bovine serum (FBS; Biological Industries, 04-0101-1, Cromwell, CT, USA) under a humidified atmosphere of 5% CO~2~ at 37°C. Twenty-two clinical hepatocellular carcinoma tissues and matched adjacent normal hepatic tissues were collected from hepatocellular carcinoma patients who underwent surgery at the First Affiliated Hospital of Medical College, Zhejiang University (Hangzhou, China). All procedures performed in this study involving human participants were conducted in accordance with the ethical standards of the First Affiliated Hospital of Medical College, Zhejiang University. The written informed consent from every participant was obtained.

RNA Extraction, Reverse Transcription PCR and Quantitative Real-Time PCR (qRT-PCR)
----------------------------------------------------------------------------------

RNA extraction, reverse transcription PCR and quantitative real-time fluorescence PCR were conducted as previously described ([@B24], [@B25]). Total RNA was first extracted from cells and clinical samples using RNAiso plus Reagent (TaKaRa, Kusatsu, Japan), after which total RNA was reversely transcribed into complementary DNA (cDNA) by the PrimeScript^TM^ RT Reagent Kit (TaKaRa, RR037A). Then, qRT-PCR was performed using SYBR Premix Ex Taq (TaKaRa, RR420A) in a Roche LightCycle480 II Real-Time PCR Detection System. GAPDH was employed as the internal control for gene expression analysis. Gene expression was normalized to GAPDH and calculated through the comparative threshold method of 2^−ΔΔ*CT*^. All primers used in this study were listed [Table S1](#SM1){ref-type="supplementary-material"}.

Cell Transfection
-----------------

20 × 10^4^ of hepG2 and LM3 cells were seeded into 6-well plates and cultured for 12 h. Then, miRNA mimics and negative controls were transfected into these cells using Opti-MEM and Lipofectamine 3000 reagents (Invitrogen, Shanghai, China) according to the manufacturer\'s instruction. At 12 h post-transfection, the medium was replaced with fresh DMEM. The miRNA mimics and negative controls were synthesized and purchased from RiboBio Co. Ltd. (Guangzhou, China).

Statistical Analysis
--------------------

Most of the statistical analyses were done by the bioinformatic online tools as mentioned above. *P*-values from GEPIA expression analysis, logrank *P*-values from GEPIA and Kaplan-Meier plotter survival analysis were corrected by false discovery rate and other reported *P*-values by online tools were not adjusted for false discovery rate correction. The statistical analyses of experimental data were conducted by GraphPad Prism software (version 7.0.3). Experiments were performed in triplicates and shown as mean ± standard deviation (SD) from at least three independent times.

Student\'s *t*-test (two tailed) were employed to do comparisons between two groups. ROC curve was utilized to assess diagnostic effect. Logrank *P* \< 0.05 or *P* \< 0.05 was considered as statistically significant.

Results {#s3}
=======

CELSR3, GPSM2, and CHEK1 Were Identified as Three Novel Prognosis-Associated Genes in Hepatocellular Carcinoma
--------------------------------------------------------------------------------------------------------------

To obtain the genes most associated with patient survival in hepatocellular carcinoma, GEPIA database was first utilized. In this study, two indices regarding to patients\' outcome, overall survival (OS) and disease-free survival (RFS), were included. The top 100 OS-associated genes and the top 100 RFS-associated genes were identified as listed in [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, respectively. By intersecting OS-associated genes and RFS-associated genes, 9 genes (CLEC3B, DNASE1L3, PTTG1, CELSR3, GPSM2, KIF2C, XPO5, UBE2S, and CHEK1) were defined as candidate genes, which were commonly appeared in OS-associated gene set and RFS-associated gene set ([Figure 1A](#F1){ref-type="fig"}). After reviewing the published literatures and previous studies, we found that 6 of 9 genes \[CLEC3B ([@B26]), DNASE1L3 ([@B27]), PTTG1 ([@B28], [@B29]), KIF2C ([@B30]), XPO5 ([@B31], [@B32]), and UBE2S ([@B33], [@B34])\] have been demonstrated to act as promising prognostic biomarkers for hepatocellular carcinoma. The rest three genes (CELSR3, GPSM2, and CHEK1) have not been studied for their prognostic values in hepatocellular carcinoma so far. Therefore, CELSR3, GPSM2 and CHEK1 were considered as three novel potential prognostic biomarkers for hepatocellular carcinoma. The prognostic values (OS and RFS) of CELSR3, GPSM2, and CHEK1 were presented in [Figures 1B--G](#F1){ref-type="fig"}. The results suggested that high expression of CELSR3, GPSM2, or CHEK1 indicated poor prognosis in patients with hepatocellular carcinoma.

###### 

The genes most associated with overall survival (OS) of patients with hepatocellular carcinoma determined by GEPIA database.

  **Gene symbol**   **Gene ID**                                **Logrank *P*-value**
  ----------------- ------------------------------------------ -----------------------
  HILPDA            [ENSG00000135245.9](ENSG00000135245.9)     0.0000000076
  CCDC58            [ENSG00000160124.9](ENSG00000160124.9)     0.0000000558
  B3GAT3            [ENSG00000149541.9](ENSG00000149541.9)     0.00000023
  CLEC3B            [ENSG00000163815.5](ENSG00000163815.5)     0.000000243
  CTB-147N14.6      [ENSG00000275719.1](ENSG00000275719.1)     0.000000255
  SOCS2             [ENSG00000120833.13](ENSG00000120833.13)   0.000000917
  LPCAT1            [ENSG00000153395.9](ENSG00000153395.9)     0.00000125
  PES1              [ENSG00000100029.17](ENSG00000100029.17)   0.00000179
  DNASE1L3          [ENSG00000163687.13](ENSG00000163687.13)   0.00000187
  AHSA1             [ENSG00000100591.7](ENSG00000100591.7)     0.00000192
  RP11-286H15.1     [ENSG00000272789.1](ENSG00000272789.1)     0.00000225
  SAC3D1            [ENSG00000168061.13](ENSG00000168061.13)   0.00000234
  SEC61G            [ENSG00000132432.13](ENSG00000132432.13)   0.00000293
  RP11-295D4.1      [ENSG00000262712.1](ENSG00000262712.1)     0.00000297
  RHPN1-AS1         [ENSG00000254389.3](ENSG00000254389.3)     0.00000365
  MTCH1             [ENSG00000137409.18](ENSG00000137409.18)   0.00000369
  PTTG1             [ENSG00000164611.12](ENSG00000164611.12)   0.00000379
  SAMD13            [ENSG00000203943.8](ENSG00000203943.8)     0.00000388
  CDC20             [ENSG00000117399.13](ENSG00000117399.13)   0.000004
  RPUSD3            [ENSG00000156990.14](ENSG00000156990.14)   0.00000424
  SLC41A3           [ENSG00000114544.15](ENSG00000114544.15)   0.00000436
  STEAP1B           [ENSG00000105889.14](ENSG00000105889.14)   0.00000518
  CCDC137           [ENSG00000185298.12](ENSG00000185298.12)   0.00000563
  MED19             [ENSG00000156603.14](ENSG00000156603.14)   0.00000611
  SNRPEP2           [ENSG00000256968.1](ENSG00000256968.1)     0.00000686
  LINC01134         [ENSG00000236423.5](ENSG00000236423.5)     0.00000698
  NRAV              [ENSG00000248008.2](ENSG00000248008.2)     0.00000704
  TMEM185B          [ENSG00000226479.3](ENSG00000226479.3)     0.00000708
  HM13              [ENSG00000101294.16](ENSG00000101294.16)   0.00000714
  NAP1L1P1          [ENSG00000254759.1](ENSG00000254759.1)     0.00000758
  CELSR3            [ENSG00000008300.14](ENSG00000008300.14)   0.00000768
  GNL2              [ENSG00000134697.12](ENSG00000134697.12)   0.00000847
  EIF2S2            [ENSG00000125977.6](ENSG00000125977.6)     0.00000941
  GPSM2             [ENSG00000121957.12](ENSG00000121957.12)   0.00000964
  TIMM23            [ENSG00000265354.3](ENSG00000265354.3)     0.00000985
  PPM1G             [ENSG00000115241.10](ENSG00000115241.10)   0.00000989
  BTNL9             [ENSG00000165810.16](ENSG00000165810.16)   0.00001
  SLC29A3           [ENSG00000198246.7](ENSG00000198246.7)     0.0000101
  KIF2C             [ENSG00000142945.12](ENSG00000142945.12)   0.0000108
  MPV17             [ENSG00000115204.14](ENSG00000115204.14)   0.000011
  SCML2             [ENSG00000102098.17](ENSG00000102098.17)   0.0000122
  TMEM251           [ENSG00000153485.5](ENSG00000153485.5)     0.0000122
  MUTYH             [ENSG00000132781.17](ENSG00000132781.17)   0.000013
  EIF2B5            [ENSG00000145191.11](ENSG00000145191.11)   0.0000134
  LRRC41            [ENSG00000132128.16](ENSG00000132128.16)   0.0000141
  ATP1B3            [ENSG00000069849.10](ENSG00000069849.10)   0.0000142
  UQCRH             [ENSG00000173660.11](ENSG00000173660.11)   0.0000143
  RAB42             [ENSG00000188060.6](ENSG00000188060.6)     0.0000143
  DTYMK             [ENSG00000168393.12](ENSG00000168393.12)   0.0000144
  PIGU              [ENSG00000101464.10](ENSG00000101464.10)   0.0000144
  FAM189B           [ENSG00000160767.20](ENSG00000160767.20)   0.0000145
  ZNF576            [ENSG00000124444.15](ENSG00000124444.15)   0.0000151
  RRP12             [ENSG00000052749.13](ENSG00000052749.13)   0.0000154
  TAF3              [ENSG00000165632.7](ENSG00000165632.7)     0.0000163
  GARS              [ENSG00000106105.13](ENSG00000106105.13)   0.0000169
  XPO5              [ENSG00000124571.17](ENSG00000124571.17)   0.0000169
  ERGIC3            [ENSG00000125991.18](ENSG00000125991.18)   0.0000172
  CLTA              [ENSG00000122705.16](ENSG00000122705.16)   0.0000177
  SLC16A3           [ENSG00000141526.14](ENSG00000141526.14)   0.000018
  KIFC1             [ENSG00000237649.7](ENSG00000237649.7)     0.0000198
  EIF5B             [ENSG00000158417.10](ENSG00000158417.10)   0.0000215
  CMB9-22P13.1      [ENSG00000173727.11](ENSG00000173727.11)   0.0000221
  TRPC4AP           [ENSG00000100991.11](ENSG00000100991.11)   0.0000224
  GAPDH             [ENSG00000111640.14](ENSG00000111640.14)   0.0000227
  CCT3              [ENSG00000163468.14](ENSG00000163468.14)   0.0000232
  BRK1              [ENSG00000254999.3](ENSG00000254999.3)     0.0000232
  CDC42EP2          [ENSG00000149798.4](ENSG00000149798.4)     0.0000234
  TMEM106C          [ENSG00000134291.11](ENSG00000134291.11)   0.0000257
  POLR2L            [ENSG00000177700.5](ENSG00000177700.5)     0.0000264
  UBE2S             [ENSG00000108106.13](ENSG00000108106.13)   0.0000278
  COMMD3            [ENSG00000148444.15](ENSG00000148444.15)   0.0000279
  PPP1R14B          [ENSG00000173457.10](ENSG00000173457.10)   0.0000292
  MRPL11            [ENSG00000174547.13](ENSG00000174547.13)   0.0000294
  SLC11A1           [ENSG00000018280.16](ENSG00000018280.16)   0.00003
  CHEK1             [ENSG00000149554.12](ENSG00000149554.12)   0.0000303
  SRD5A3            [ENSG00000128039.10](ENSG00000128039.10)   0.0000311
  UCK2              [ENSG00000143179.12](ENSG00000143179.12)   0.0000317
  MKLN1-AS          [ENSG00000236753.5](ENSG00000236753.5)     0.0000335
  RP5-864K19.4      [ENSG00000228436.2](ENSG00000228436.2)     0.0000343
  KRBA1             [ENSG00000133619.17](ENSG00000133619.17)   0.0000345
  TMEM147           [ENSG00000105677.11](ENSG00000105677.11)   0.0000355
  CTC-297N7.9       [ENSG00000264016.2](ENSG00000264016.2)     0.0000357
  HCFC1             [ENSG00000172534.13](ENSG00000172534.13)   0.0000363
  ILKAP             [ENSG00000132323.8](ENSG00000132323.8)     0.0000364
  AGTRAP            [ENSG00000177674.15](ENSG00000177674.15)   0.0000364
  MAPKAPK5-AS1      [ENSG00000234608.7](ENSG00000234608.7)     0.000037
  NKX3-2            [ENSG00000109705.7](ENSG00000109705.7)     0.0000375
  UPF3B             [ENSG00000125351.10](ENSG00000125351.10)   0.0000377
  RRP8              [ENSG00000132275.10](ENSG00000132275.10)   0.0000416
  ABCC5             [ENSG00000114770.16](ENSG00000114770.16)   0.0000422
  C4orf47           [ENSG00000205129.8](ENSG00000205129.8)     0.0000423
  CDKN2C            [ENSG00000123080.10](ENSG00000123080.10)   0.0000426
  CCT4              [ENSG00000115484.14](ENSG00000115484.14)   0.0000437
  NUP37             [ENSG00000075188.8](ENSG00000075188.8)     0.0000442
  RAB24             [ENSG00000169228.13](ENSG00000169228.13)   0.0000445
  MED10             [ENSG00000133398.3](ENSG00000133398.3)     0.0000456
  MIR210HG          [ENSG00000247095.2](ENSG00000247095.2)     0.0000458
  SLC1A5            [ENSG00000105281.12](ENSG00000105281.12)   0.0000467
  SMS               [ENSG00000102172.15](ENSG00000102172.15)   0.000047
  AP001469.9        [ENSG00000239415.1](ENSG00000239415.1)     0.000047

###### 

The genes most associated with disease-free survival (RFS) of patients with hepatocellular carcinoma determined by GEPIA database.

  **Gene symbol**   **Gene ID**                                **Logrank *P*-value**
  ----------------- ------------------------------------------ -----------------------
  XPO5              [ENSG00000124571.17](ENSG00000124571.17)   0.000000141
  PCNT              [ENSG00000160299.16](ENSG00000160299.16)   0.000000524
  RP11-218F10.3     [ENSG00000273449.1](ENSG00000273449.1)     0.00000195
  CCNB1             [ENSG00000134057.14](ENSG00000134057.14)   0.00000219
  AC010761.8        [ENSG00000264577.1](ENSG00000264577.1)     0.00000257
  BRD8              [ENSG00000112983.17](ENSG00000112983.17)   0.00000315
  RHOT2             [ENSG00000140983.13](ENSG00000140983.13)   0.00000329
  MYO19             [ENSG00000278259.4](ENSG00000278259.4)     0.00000341
  CDC25C            [ENSG00000158402.18](ENSG00000158402.18)   0.00000642
  GPSM2             [ENSG00000121957.12](ENSG00000121957.12)   0.00000688
  HIST1H1B          [ENSG00000184357.4](ENSG00000184357.4)     0.00000743
  STX1A             [ENSG00000106089.11](ENSG00000106089.11)   0.00000879
  TRIM45            [ENSG00000134253.9](ENSG00000134253.9)     0.00000912
  NUP85             [ENSG00000125450.10](ENSG00000125450.10)   0.0000102
  CENPK             [ENSG00000123219.12](ENSG00000123219.12)   0.0000112
  LRP11             [ENSG00000120256.9](ENSG00000120256.9)     0.0000117
  XCR1              [ENSG00000173578.7](ENSG00000173578.7)     0.0000138
  CLEC3B            [ENSG00000163815.5](ENSG00000163815.5)     0.0000145
  RAD51C            [ENSG00000108384.14](ENSG00000108384.14)   0.0000153
  BRCA1             [ENSG00000012048.19](ENSG00000012048.19)   0.0000154
  PRR3              [ENSG00000204576.11](ENSG00000204576.11)   0.0000156
  CAD               [ENSG00000084774.13](ENSG00000084774.13)   0.0000159
  MCM6              [ENSG00000076003.4](ENSG00000076003.4)     0.0000164
  RPL14P3           [ENSG00000241923.2](ENSG00000241923.2)     0.0000168
  PSMC3IP           [ENSG00000131470.14](ENSG00000131470.14)   0.0000174
  ADH4              [ENSG00000198099.8](ENSG00000198099.8)     0.0000177
  PTTG1             [ENSG00000164611.12](ENSG00000164611.12)   0.0000186
  MED7              [ENSG00000155868.7](ENSG00000155868.7)     0.0000199
  SRP68             [ENSG00000167881.14](ENSG00000167881.14)   0.0000207
  SNHG20            [ENSG00000234912.9](ENSG00000234912.9)     0.0000219
  PARPBP            [ENSG00000185480.11](ENSG00000185480.11)   0.0000221
  CHAF1B            [ENSG00000159259.7](ENSG00000159259.7)     0.0000224
  RP11-197P3.5      [ENSG00000229587.2](ENSG00000229587.2)     0.0000232
  CHEK1             [ENSG00000149554.12](ENSG00000149554.12)   0.0000241
  KPNA2             [ENSG00000182481.8](ENSG00000182481.8)     0.0000254
  E2F8              [ENSG00000129173.12](ENSG00000129173.12)   0.0000258
  C2orf66           [ENSG00000187944.2](ENSG00000187944.2)     0.0000266
  EFTUD2            [ENSG00000108883.12](ENSG00000108883.12)   0.0000266
  SCRT1             [ENSG00000261678.2](ENSG00000261678.2)     0.0000272
  RP11-127B20.3     [ENSG00000272677.1](ENSG00000272677.1)     0.0000283
  WI2-89031B12.1    [ENSG00000261773.1](ENSG00000261773.1)     0.0000302
  DHX57             [ENSG00000163214.20](ENSG00000163214.20)   0.0000319
  MKI67             [ENSG00000148773.12](ENSG00000148773.12)   0.0000337
  LMNB1             [ENSG00000113368.11](ENSG00000113368.11)   0.0000338
  RP11-709D24.8     [ENSG00000278434.1](ENSG00000278434.1)     0.0000349
  UBE2S             [ENSG00000108106.13](ENSG00000108106.13)   0.0000353
  MCM10             [ENSG00000065328.16](ENSG00000065328.16)   0.0000366
  RPL39P3           [ENSG00000235174.1](ENSG00000235174.1)     0.0000422
  NRM               [ENSG00000137404.14](ENSG00000137404.14)   0.0000424
  ZNF131            [ENSG00000172262.11](ENSG00000172262.11)   0.0000428
  LCN6              [ENSG00000267206.5](ENSG00000267206.5)     0.0000435
  RAD54L            [ENSG00000085999.11](ENSG00000085999.11)   0.0000444
  SGOL1             [ENSG00000129810.14](ENSG00000129810.14)   0.0000448
  KIF2C             [ENSG00000142945.12](ENSG00000142945.12)   0.0000449
  OLFM1             [ENSG00000130558.18](ENSG00000130558.18)   0.0000458
  FAM216A           [ENSG00000204856.11](ENSG00000204856.11)   0.000047
  RP5-967N21.11     [ENSG00000275632.1](ENSG00000275632.1)     0.0000475
  MCM3              [ENSG00000112118.17](ENSG00000112118.17)   0.0000479
  WBP2NL            [ENSG00000183066.14](ENSG00000183066.14)   0.0000484
  WDR4              [ENSG00000160193.11](ENSG00000160193.11)   0.0000501
  SLC25A19          [ENSG00000125454.11](ENSG00000125454.11)   0.0000509
  NUP205            [ENSG00000155561.14](ENSG00000155561.14)   0.0000519
  LINC01268         [ENSG00000227502.2](ENSG00000227502.2)     0.0000522
  STAG3             [ENSG00000066923.17](ENSG00000066923.17)   0.0000534
  RNFT2             [ENSG00000135119.14](ENSG00000135119.14)   0.0000535
  C5orf45           [ENSG00000161010.14](ENSG00000161010.14)   0.0000538
  RP13-516M14.1     [ENSG00000260563.3](ENSG00000260563.3)     0.0000542
  STMN1             [ENSG00000117632.20](ENSG00000117632.20)   0.0000549
  RBM28             [ENSG00000106344.8](ENSG00000106344.8)     0.0000588
  ZWINT             [ENSG00000122952.16](ENSG00000122952.16)   0.0000598
  EME1              [ENSG00000154920.14](ENSG00000154920.14)   0.00006
  PHF19             [ENSG00000119403.13](ENSG00000119403.13)   0.0000638
  C12orf43          [ENSG00000157895.11](ENSG00000157895.11)   0.0000643
  DNASE1L3          [ENSG00000163687.13](ENSG00000163687.13)   0.000066
  CENPH             [ENSG00000153044.9](ENSG00000153044.9)     0.0000663
  AP000695.4        [ENSG00000233818.1](ENSG00000233818.1)     0.0000701
  UTP18             [ENSG00000011260.13](ENSG00000011260.13)   0.0000716
  CTD-2349P21.9     [ENSG00000266490.1](ENSG00000266490.1)     0.0000729
  NASP              [ENSG00000132780.16](ENSG00000132780.16)   0.0000758
  POLR3F            [ENSG00000132664.11](ENSG00000132664.11)   0.0000763
  AGAP10P           [ENSG00000230869.1](ENSG00000230869.1)     0.0000764
  EZH2              [ENSG00000106462.10](ENSG00000106462.10)   0.0000766
  DDAH2             [ENSG00000213722.8](ENSG00000213722.8)     0.0000766
  HEATR5A           [ENSG00000129493.14](ENSG00000129493.14)   0.0000786
  RP11-225B17.2     [ENSG00000273014.1](ENSG00000273014.1)     0.0000786
  RP5-1074L1.4      [ENSG00000273373.1](ENSG00000273373.1)     0.0000794
  TBRG4             [ENSG00000136270.13](ENSG00000136270.13)   0.0000799
  OMG               [ENSG00000126861.4](ENSG00000126861.4)     0.00008
  AXIN1             [ENSG00000103126.14](ENSG00000103126.14)   0.0000801
  NR2C1             [ENSG00000120798.16](ENSG00000120798.16)   0.0000802
  RP11-932O9.10     [ENSG00000269974.1](ENSG00000269974.1)     0.0000815
  SPEF1             [ENSG00000101222.12](ENSG00000101222.12)   0.0000867
  BFSP1             [ENSG00000125864.11](ENSG00000125864.11)   0.0000876
  ATRIP             [ENSG00000164053.17](ENSG00000164053.17)   0.0000879
  SPATA2            [ENSG00000158480.10](ENSG00000158480.10)   0.000091
  CELSR3            [ENSG00000008300.14](ENSG00000008300.14)   0.0000925
  CCZ1B             [ENSG00000146574.15](ENSG00000146574.15)   0.0000933
  JCHAIN            [ENSG00000132465.10](ENSG00000132465.10)   0.0000936
  UTP6              [ENSG00000108651.9](ENSG00000108651.9)     0.0000941
  RP4-620E11.8      [ENSG00000273951.1](ENSG00000273951.1)     0.0000973

![Identification of novel genes significantly associated with prognosis of hepatocellular carcinoma. **(A)** Identification of CELSR3, GPSM2, and CHEK1 as three novel genes linked to prognosis of hepatocellular carcinoma by intersecting the genes significantly associated with overall survival (OS) and disease-free survival (RFS) and excluding those genes previously studied; high expression of CELSR3 indicated poor OS **(B)** and RFS **(C)** of hepatocellular carcinoma; high expression of GPSM2 indicated poor OS **(D)** and RFS **(E)** of hepatocellular carcinoma; high expression of CHEK1 indicated poor OS **(F)** and RFS **(G)** of hepatocellular carcinoma. Logrank *P* \< 0.05 was considered as statistically significant.](fonc-10-00340-g0001){#F1}

CELSR3, GPSM2, and CHEK1 Were Upregulated in Hepatocellular Carcinoma
---------------------------------------------------------------------

Next, we intended to determine expression levels of three novel prognosis-associated genes in hepatocellular carcinoma by bioinformatic analysis and experimental validation. Firstly, we detected their expression in TCGA hepatocellular carcinoma tissues and normal tissues using UALCAN database. CELSR3, GPSM2, and CHEK1 were significantly upregulated in tumor samples compared with normal samples as shown in [Figures 2A--C](#F2){ref-type="fig"}, respectively. Next, Oncomine database was further introduced to analyze CELSR3, GPSM2, and CHEK1 expression in hepatocellular carcinoma. The datasets met the thresholds of *P* \< 0.05 and \|fold change\| \> 1.5 were included for conducting meta-analysis. As presented in [Figures 2D--F](#F2){ref-type="fig"}, CELSR3, GPSM2, and CHEK1 expression were markedly higher in hepatocellular carcinoma than that in normal controls. Protein expression levels of CELSR3, GPSM2, and CHEK1 were evaluated using HumanProteinAtlas database. [Figures S1A,B](#SM4){ref-type="supplementary-material"} suggested that both CELSR3 and GPSM2 protein expression levels were increased in tumor tissue compared to normal tissue. However, CHEK1 protein value was not included in HumanProteinAtlas database. Subsequently, using qRT-PCR, we found that expression levels of CELSR3 ([Figure 2G](#F2){ref-type="fig"}), GPSM2 ([Figure 2H](#F2){ref-type="fig"}), and CHEK1 ([Figure 2I](#F2){ref-type="fig"}) were obviously increased in two hepatocellular carcinoma cell lines (hepG2 and LM3) when compared with normal hepatic cell line (HL7702). Moreover, compared to normal hepatic tissues, CELSR3, GPSM2, and CHEK1 expression levels were significantly upregulated in collected hepatocellular carcinoma clinical tissues as shown in [Figures 2J--L](#F2){ref-type="fig"}, respectively. All these findings demonstrate that CELSR3, GPSM2, and CHEK1 were upregulated in hepatocellular carcinoma and linked to prognosis of patients with hepatocellular carcinoma.

![The mRNA expression levels of CELSR3, GPSM2, and CHEK1 in hepatocellular carcinoma. mRNA expression of CELSR3 **(A)**, GPSM2 **(B)**, and CHEK1 **(C)** were significantly increased in tumor tissues compared to normal controls determined by UALCAN database; mRNA expression of CELSR3 **(D)**, GPSM2 **(E)**, and CHEK1 **(F)** were significantly increased in tumor tissues compared to normal controls determined by Oncomine database. CELSR3 **(G)**, GPSM2 **(H)**, and CHEK1 **(I)** were markedly upregulated in hepG2 and LM3 when compared with HL7702; mRNA expression of CELSR3 **(J)**, GPSM2 **(K)**, and CHEK1 **(L)** were obviously higher in tumor tissues than that in adjacent normal tissues; normalization was done relative to GAPDH. \**P* \< 0.05.](fonc-10-00340-g0002){#F2}

Prediction and Validation of Potential miRNAs Binding to CELSR3, GPSM2, and CHEK1
---------------------------------------------------------------------------------

Next, we predicted upstream regulatory miRNAs of CELSR3, GPSM2, and CHEK1 through a comprehensive miRNA study-associated database, miRNet. A total of 156 mRNA-miRNA pairs, including 71 CELSR3-miRNA pairs, 52 GPSM2-miRNA pairs and 33 CHEK1-miRNA pairs, were acquired. For better visualization, mRNA-miRNA interactive network was constructed using Cytoscape software as presented in [Figure 3](#F3){ref-type="fig"}. According to the classic action mechanism of miRNA in negative regulation of gene expression, there should be inverse expression relationship between the predicted mRNA-miRNA interactions. Thus, we employed starBase database to perform expression correlation analysis for these mRNA-miRNA interactions in hepatocellular carcinoma. The analytic results were shown in [Table S2](#SM2){ref-type="supplementary-material"}. Those mRNA-miRNA pairs with *R* \< −0.1 and *P* \< 0.05 were considered as significant interactions. Among the 156 interactions, only 8 mRNA-miRNA pairs, including CELSR3-hsa-mir-30a-5p, CELSR3-hsa-mir-4646-3p, CHEK1-hsa-mir-195-5p, CHEK1-hsa-mir-193b-3p, CHEK1-hsa-mir-497-5p, CHEK1-hsa-mir-139-3p, GPSM2-hsa-mir-122-5p, and GPSM2-hsa-mir-378a-5p, were identified as significant interactions ([Figure 4](#F4){ref-type="fig"}). Theoretically, miRNAs that potentially bind to oncogenic CELSR3, GPSM2, and CHEK1 should be downregulated in hepatocellular carcinoma and display favorable prognostic roles. The expression levels of these potential miRNAs and their prognostic roles in hepatocellular carcinoma were determined using starBase database and Kaplan-Meier plotter database, respectively. By combination of expression analysis and survival analysis, hsa-mir-195-5p, hsa-mir-497-5p, hsa-mir-139-3p, and hsa-mir-122-5p were the potential miRNAs in hepatocellular carcinoma ([Figures 5A--H](#F5){ref-type="fig"}). Subsequently, we further determined expression change of target gene (CHEK1 or GPSM2) after overexpression of hsa-mir-195-5p, hsa-mir-497-5p, hsa-mir-139-3p, or hsa-mir-122-5p in hepG2 and LM3 cell lines. [Figures 5I,J](#F5){ref-type="fig"} showed a significant reduction of CHEK1 expression after overexpression of hsa-mir-195-5p and hsa-mir-497-5p; [Figure 5K](#F5){ref-type="fig"} revealed that upregulation of hsa-mir-139-3p did not influence CHEK1 expression; [Figure 5L](#F5){ref-type="fig"} demonstrated that GPSM2 expression was significantly downregulated after overexpression of hsa-mir-122-5p. All these results together indicate that CHEK1-hsa-mir-195-5p/hsa-mir-497-5p and GPSM2-hsa-mir-122-5p may be key pathways in mediating progression of hepatocellular carcinoma and that link to patients\' prognosis.

![Construction of CELSR3/GPSM2/CHEK1-miRNA network by miRNet database and Cytoscape software.](fonc-10-00340-g0003){#F3}

![Significantly correlated mRNA-miRNA pairs determined by starBase database. **(A)** Expression of hsa-mir-30a-5p was negatively associated with CELSR3 expression; **(B)** expression of hsa-mir-4646-3p was negatively associated with CELSR3 expression; **(C)** expression of hsa-mir-195-5p was negatively associated with CHEK1 expression; **(D)** expression of hsa-mir-193b-3p was negatively associated with CHEK1 expression; **(E)** expression of hsa-mir-497-5p was negatively associated with CHEK1 expression; **(F)** expression of hsa-mir-139-3p was negatively associated with CHEK1 expression; **(G)** expression of hsa-mir-122-5p was negatively associated with GPSM2 expression; **(H)** expression of hsa-mir-378a-5p was negatively associated with GPSM2 expression.](fonc-10-00340-g0004){#F4}

![Identification of the most potential miRNAs associated with prognosis of hepatocellular carcinoma. Expression and prognostic value of hsa-mir-30a-5p **(A)**, hsa-mir-4646-3p **(B)**, hsa-mir-195-5p **(C)**, hsa-mir-193b-3p **(D)**, hsa-mir-497-5p **(E)**, hsa-mir-139-3p **(F)**, hsa-mir-122-5p **(G)**, and hsa-mir-378a-5p **(H)** in hepatocellular carcinoma; **(I)** after overexpression of hsa-mir-195-5p, mRNA expression of CHEK1 was significantly decreased in hepG2 and LM3; **(J)** after overexpression of hsa-mir-497-5p, mRNA expression of CHEK1 was significantly decreased in hepG2 and LM3; **(K)** after overexpression of hsa-mir-139-3p, no significant downregulation of CHEK1 mRNA expression was observed in hepG2 and LM3; **(L)** after overexpression of hsa-mir-122-5p, mRNA expression of GPSM2 was significantly decreased in hepG2 and LM3. \**P* \< 0.05.](fonc-10-00340-g0005){#F5}

Prediction and Validation of Key lncRNAs Binding to Potential miRNAs
--------------------------------------------------------------------

Previous studies have suggested that lncRNAs can bind to miRNA, and mediate regulation of target gene expression and play biological roles ([@B35], [@B36]). Thus, two databases, miRNet and starBase, were used to predict potential lncRNAs that may bind to hsa-mir-195-5p, hsa-mir-497-5p and hsa-mir-122-5p. One hundred and forty five and Two hundred and eighty four lncRNAs were predicted to target hsa-mir-195-5p by miRNet and starBase, respectively; 146 and 284 lncRNAs were predicted to target hsa-mir-497-5p by miRNet and starBase, respectively; 21 and 92 lncRNAs were predicted to target hsa-mir-122-5p by miRNet and starBase, respectively (Data were not shown). As shown in [Figures 6A--C](#F6){ref-type="fig"}, 33, 33, and 6 lncRNAs binding to hsa-mir-195-5p, hsa-mir-497-5p, and hsa-mir-122-5p were commonly appeared in both miRNet and starBase databases. These lncRNAs were selected for subsequent analysis. For better visualization, the miRNA-lncRNA regulatory network was established by Cytoscape software ([Figure 6D](#F6){ref-type="fig"}). Based on ceRNA hypothesis, lncRNAs targeting to hsa-mir-195-5p, hsa-mir-497-5p, and hsa-mir-122-5p should be oncogenic lncRNAs in hepatocellular carcinoma. By combination of expression analysis and survival analysis ([Figure 7A](#F7){ref-type="fig"}), we found that nine lncRNAs, including SNHG1 ([Figure 7B](#F7){ref-type="fig"}), SNHG12 ([Figure 7C](#F7){ref-type="fig"}), LINC00511 ([Figure 7D](#F7){ref-type="fig"}), HCG18 ([Figure 7E](#F7){ref-type="fig"}), FGD5-AS1 ([Figure 7F](#F7){ref-type="fig"}), CERS6-AS1 ([Figure 7G](#F7){ref-type="fig"}), NUTM2A-AS1 ([Figure 7H](#F7){ref-type="fig"}), SNHG16 ([Figure 7I](#F7){ref-type="fig"}), and ASB16-AS1 ([Figure 7J](#F7){ref-type="fig"}), were significantly upregulated in hepatocellular carcinoma, and their upregulation linked to poor prognosis of patients with hepatocellular carcinoma. The current findings support that SNHG1, SNHG12, LINC00511, HCG18, FGD5-AS1, CERS6-AS1, NUTM2A-AS1, SNHG16, and ASB16-AS1, upregulated and linked to poor prognosis in hepatocellular carcinoma, might be the most potential lncRNAs that bind to previous identified miRNAs, hsa-mir-195-5p, hsa-mir-497-5p, and hsa-mir-122-5p.

![Prediction of upstream lncRNAs potentially binding to hsa-mir-195-5p, hsa-mir-497-5p, and hsa-mir-122-5p. **(A)** Potential lncRNAs of hsa-mir-195-5p predicted by miRNet and starBase databases; **(B)** potential lncRNAs of hsa-mir-497-5p predicted by miRNet and starBase databases; **(C)** potential lncRNAs of hsa-mir-122-5p predicted by miRNet and starBase databases; **(D)** establishment of miRNA-lncRNA network using Cytoscape software.](fonc-10-00340-g0006){#F6}

![Expression analysis and survival analysis of potential lncRNAs in hepatocellular carcinoma. **(A)** SNHG1, SNHG12, LINC00511, HCG18, FGD5-AS1, CERS6-AS1, NUTM2A-AS1, SNHG16, and ASB16-AS1 were identified as key lncRNAs in hepatocellular carcinoma by combination of their expression levels and prognostic values; **(B)** SNHG1 was significantly upregulated in tumor tissues and linked to poor prognosis of hepatocellular carcinoma; **(C)** SNHG12 was significantly upregulated in tumor tissues and linked to poor prognosis of hepatocellular carcinoma; **(D)** LINC00511 was significantly upregulated in tumor tissues and linked to poor prognosis of hepatocellular carcinoma; **(E)** HCG18 was significantly upregulated in tumor tissues and linked to poor prognosis of hepatocellular carcinoma; **(F)** FGD5-AS1 was significantly upregulated in tumor tissues and linked to poor prognosis of hepatocellular carcinoma; **(G)** CERS6-AS1 was significantly upregulated in tumor tissues and linked to poor prognosis of hepatocellular carcinoma; **(H)** NUTM2A-AS1 was significantly upregulated in tumor tissues and linked to poor prognosis of hepatocellular carcinoma; **(I)** SNHG16 was significantly upregulated in tumor tissues and linked to poor prognosis of hepatocellular carcinoma; **(J)** ASB16-AS1 was significantly upregulated in tumor tissues and linked to poor prognosis of hepatocellular carcinoma. \**P* \< 0.05.](fonc-10-00340-g0007){#F7}

Prediction and Validation of Upstream miRNA-lncRNA Network of "Known" mRNA in Hepatocellular Carcinoma
------------------------------------------------------------------------------------------------------

Next, based on ceRNA mechanism, we further constructed a six "known" genes-miRNA-lncRNA network in hepatocellular carcinoma. Firstly, we predicted upstream miRNAs of CLEC3B, DNASE1L3, PTTG1, KIF2C, XPO5, and UBE2S using miRNet. As shown in [Table S3](#SM3){ref-type="supplementary-material"}, a total of 165 miRNA-mRNA pairs were predicted. Then, we performed expression correlation analysis for the 165 miRNA-mRNA pairs in hepatocellular carcinoma, and found that only 13 pairs presented significantly negative relationship about their expression ([Table S3](#SM3){ref-type="supplementary-material"}). Expression and survival analyses revealed that 4 miRNAs (hsa-miR-101-3p, hsa-miR-148a-3p, hsa-miR-4524a-3p, and hsa-miR-122-5p) were significantly downregulated in hepatocellular carcinoma and correlated with favorable prognosis ([Figures 8A--D](#F8){ref-type="fig"}). Next, we predicted the upstream lncRNAs of the 4 miRNAs through miRNet and starBase databases. As presented in [Figures 8E--G](#F8){ref-type="fig"}, 7, 16, and 5 lncRNAs were identified to potentially bind to hsa-miR-101-3p, hsa-miR-148a-3p, and hsa-miR-122-5p, respectively. No potential lncRNAs of hsa-miR-4524a-3p were found. Expression and survival analyses demonstrated that, among these predicted lncRNAs, SNHG1 ([Figure 7B](#F7){ref-type="fig"}), HCG18 ([Figure 7E](#F7){ref-type="fig"}), NUTM2A-AS1 ([Figure 7H](#F7){ref-type="fig"}) and ASB16-AS1 ([Figure 7J](#F7){ref-type="fig"}), and SNHG6 ([Figures 8H,I](#F8){ref-type="fig"}) were markedly upregulated in hepatocellular carcinoma and linked to poor prognosis.

![Prediction and validation of upstream miRNAs and lncRNAs of six "known" genes. Expression and prognostic value of hsa-mir-101-3p **(A)**, hsa-mir-148a-3p **(B)**, hsa-mir-4524a-3p **(C)**, hsa-mir-122-5p **(D)**. Potential lncRNAs of hsa-mir-101-3p **(E)**, hsa-mir-148a-3p **(F)**, hsa-mir-122-5p **(G)**, predicted by miRNet and starBase. **(H)** Expression of SNHG6 in hepatocellular carcinoma analyzed by GEPIA. **(I)** The prognostic value of SNHG6 in hepatocellular carcinoma assessed by GEPIA database.](fonc-10-00340-g0008){#F8}

Establishment of Key mRNA-miRNA-lncRNA Triple ceRNA Network in Hepatocellular Carcinoma
---------------------------------------------------------------------------------------

10 potential lncRNAs (SNHG1, SNHG12, LINC00511, HCG18, FGD5-AS1, CERS6-AS1, NUTM2A-AS1, SNHG16, ASB16-AS1, SNHG6) together with 5 potential miRNAs (hsa-miR-195-5p, hsa-miR-497-5p, hsa-miR-122-5p, hsa-miR-101-3p, and hsa-miR-148a-3p) made up a miRNA-lncRNA sub-network. After performing expression correlation analysis, we discovered that 14 of 21 interactions (hsa-miR-195-5p-SNHG1, hsa-miR-195-5p-LINC00511, hsa-miR-195-5p-HCG18, hsa-miR-195-5p-NUTM2A-AS1, hsa-miR-195-5p-SNHG16, hsa-miR-497-5p-SNHG1, hsa-miR-497-5p-HCG18, hsa-miR-497-5p-NUTM2A-AS1, hsa-miR-497-5p-SNHG16, hsa-miR-122-5p-ASB16-AS1, hsa-miR-101-3p-SNHG1, hsa-miR-101-3p-SNHG6, hsa-miR-148a-3p-HCG18, and hsa-miR-148a-3p-NUTM2A-AS1) possessed significant negative expression relationships ([Table 3](#T3){ref-type="table"}). The 7 lncRNAs (SNHG1, LINC00511, HCG18, NUTM2A-AS1, SNHG16, ASB16-AS1, and SNHG6) may potentially modulate CHEK1, GPSM2, XPO5, and KIF2C by competitively binding to shared miRNAs (hsa-miR-195-5p, hsa-miR-497-5p, hsa-miR-122-5p, hsa-miR-101-3p, and has-miR-148a-3p). According to ceRNA hypothesis, there should be positive association between mRNA expression and lncRNA expression. Two databases, starBase and GEPIA, were employed to analyze expression correlation of 11 mRNA-lncRNA pairs (CHEK1-SNHG1, CHEK1-LINC00511, CHEK1-HCG18, CHEK1-NUTM2A-AS1, CHEK1-SNHG16, and GPSM2-ASB16-AS1, XPO5-ASB16-AS1, KIF2C-SNHG1, KIF2C-SNHG6, KIF2C-HCG18, and KIF2C-NUTM2A-AS1). Notably, as presented in [Figure 9](#F9){ref-type="fig"}, [Figure S2](#SM5){ref-type="supplementary-material"}, significant positive expression associations of all these mRNA-lncRNA pairs were observed in both starBase and miRNet databases. By integration of results from *in silico* analysis and experimental validation, we established a key mRNA-miRNA-lncRNA triple regulatory network associated with prognosis of hepatocellular carcinoma ([Figure 10](#F10){ref-type="fig"}). Finally, we wanted to ascertain if these RNAs in the established mRNA-miRNA-lncRNA triple regulatory network possessed diagnostic roles in hepatocellular carcinoma. As shown in [Figure 11](#F11){ref-type="fig"}, each RNA, including 4 mRNAs (CHEK1, GPSM2, KIF2C, XPO5), 5 miRNAs (hsa-miR-195-5p, hsa-miR-497-5p, hsa-miR-122-5p, hsa-miR-101-3p, hsa-miR-148a-3p) and 7 lncRNAs (SNHG1, HCG18, NUTM2A-AS1, SNHG16, LINC00511, ASB16-AS1, SNHG6), exhibited high diagnostic value for distinguishing hepatocellular carcinoma samples from normal samples.

###### 

The correlation between potential miRNA-lncRNA pairs identified by starBase (The pairs conformed to the ceRNA hypothesis are marked with **Bold type**).

  **miRNA**             **lncRNA**       ***R***       ***P*-value**
  --------------------- ---------------- ------------- ---------------
  **hsa-mir-195-5p**    **SNHG1**        **−0.151**    **0.004**
  hsa-mir-195-5p        SNHG12           **--**0.095   0.067
  **hsa-mir-195-5p**    **LINC00511**    **−0.147**    **0.004**
  **hsa-mir-195-5p**    **HCG18**        **−0.196**    **0.000**
  hsa-mir-195-5p        FGD5-AS1         0.050         0.334
  hsa-mir-195-5p        CERS6-AS1        **--**0.003   0.960
  **hsa-mir-195-5p**    **NUTM2A-AS1**   **−0.210**    **0.000**
  **hsa-mir-195-5p**    **SNHG16**       **−0.164**    **0.002**
  **hsa-mir-497-5p**    **SNHG1**        **−0.139**    **0.008**
  hsa-mir-497-5p        SNHG12           **--**0.050   0.342
  hsa-mir-497-5p        LINC00511        **--**0.085   0.103
  **hsa-mir-497-5p**    **HCG18**        **−0.259**    **0.000**
  hsa-mir-497-5p        FGD5-AS1         **--**0.050   0.338
  hsa-mir-497-5p        CERS6-AS1        **--**0.012   0.825
  **hsa-mir-497-5p**    **NUTM2A-AS1**   **−0.202**    **0.000**
  **hsa-mir-497-5p**    **SNHG16**       **−0.273**    **0.000**
  **hsa-mir-122-5p**    **ASB16-AS1**    **−0.291**    **0.000**
  **hsa-mir-101-3p**    **SNHG1**        **−0.357**    **0.000**
  **hsa-mir-101-3p**    **SNHG6**        **−0.383**    **0.000**
  **hsa-mir-148a-3p**   **HCG18**        **−0.259**    **0.000**
  **hsa-mir-148a-3p**   **NUTM2A-AS1**   **−0.202**    **0.000**

![Correlation analysis of potential mRNA-lncRNA pairs in hepatocellular carcinoma determined by starBase. **(A)** SNHG1 expression was significantly positively correlated with CHEK1 expression in hepatocellular carcinoma; **(B)** LINC00511 expression was significantly positively correlated with CHEK1 expression in hepatocellular carcinoma; **(C)** HCG18 expression was significantly positively correlated with CHEK1 expression in hepatocellular carcinoma; **(D)** NUTM2A-AS1 expression was significantly positively correlated with CHEK1 expression in hepatocellular carcinoma; **(E)** SNHG16 expression was significantly positively correlated with CHEK1 expression in hepatocellular carcinoma; **(F)** ASB16-AS1 expression was significantly positively correlated with GPSM2 expression in hepatocellular carcinoma; **(G)** ASB16-AS1 expression was significantly positively correlated with XPO5 expression in hepatocellular carcinoma; **(H)** SNHG1 expression was significantly positively correlated with KIF2C expression in hepatocellular carcinoma; **(I)** SNHG6 expression was significantly positively correlated with KIF2C expression in hepatocellular carcinoma; **(J)** HCG18 expression was significantly positively correlated with KIF2C expression in hepatocellular carcinoma; **(K)** NUTM2A-AS1 expression was significantly positively correlated with KIF2C expression in hepatocellular carcinoma.](fonc-10-00340-g0009){#F9}

![The established mRNA-miRNA-lncRNA competing endogenous RNA (ceRNA) triple network associated with progression and prognosis of hepatocellular carcinoma.](fonc-10-00340-g0010){#F10}

![The diagnostic values of 16 potential molecules in hepatocellular carcinoma. **(A)** CHEK1 ROC analysis in hepatocellular carcinoma; **(B)** GPSM2 ROC analysis in hepatocellular carcinoma; **(C)** KIF2C ROC analysis in hepatocellular carcinoma; **(D)** XPO5 ROC analysis in hepatocellular carcinoma; **(E)** hsa-mir-195-5p ROC analysis in hepatocellular carcinoma; **(F)** hsa-mir-497-5p ROC analysis in hepatocellular carcinoma; **(G)** hsa-mir-122-5p ROC analysis in hepatocellular carcinoma; **(H)** hsa-mir-101-3p ROC analysis in hepatocellular carcinoma; **(I)** hsa-mir-148a-5p ROC analysis in hepatocellular carcinoma; **(J)** SNHG1 ROC analysis in hepatocellular carcinoma; **(K)** HCG18 ROC analysis in hepatocellular carcinoma; **(L)** NUTM2A-AS1 ROC analysis in hepatocellular carcinoma; **(M)** SNHG16 ROC analysis in hepatocellular carcinoma; **(N)** LINC00511 ROC analysis in hepatocellular carcinoma; **(O)** ASB16-AS1 ROC analysis in hepatocellular carcinoma. **(P)** SNHG6 ROC analysis in hepatocellular carcinoma. ROC, receiver operating characteristic. *P* \< 0.05 was considered as statistically significant.](fonc-10-00340-g0011){#F11}

Discussion {#s4}
==========

Hepatocellular carcinoma is notorious for its poor prognosis and high aggressiveness. Elucidation of molecular mechanisms of hepatocellular carcinoma pathogenesis and identification of promising biomarkers for diagnosis and prognosis of hepatocellular carcinoma are critical for updating therapeutic approaches and improving patients\' outcome. ceRNA regulatory network has been reported to participate in initiation and progression of human cancers. To our knowledge, a comprehensive ceRNA regulatory network based on the order model of mRNA-miRNA-lncRNA in hepatocellular carcinoma has not been constructed so far. Therefore, we tried to establish a prognosis/diagnosis-associated mRNA-miRNA-lncRNA ceRNA triple sub-network in hepatocellular carcinoma. By performing survival (OS and RFS) analysis using TCGA hepatocellular carcinoma data, nine genes including three novel genes (CELSR3, GPSM2 and CHEK1) and six "known" genes \[CLEC3B ([@B26]), DNASE1L3 ([@B27]), PTTG1 ([@B28], [@B29]), KIF2C ([@B30]), XPO5 ([@B31], [@B32]) and UBE2S ([@B33], [@B34])\] were identified as prognosis-associated genes in hepatocellular carcinoma. The prognostic values of the three novel genes in hepatocellular carcinoma have not been investigated so far. However, they have been well-documented to function as key oncogenes and biomarkers in various types of cancer. For example, Pan et al. ([@B37]) reported that CELSR3 may be a promising prognostic gene in head and neck squamous cell carcinoma; He et al. ([@B38]) demonstrated that GPSM2 facilitated tumor growth and metastasis; CHEK1 downregulation suppressed by hsa-mir-195-5p hindered growth and metastasis of non-small cell lung cancer ([@B39]). *In silico* analysis and experimental validation together suggested that the three genes were significantly upregulated in hepatocellular carcinoma. All these findings indicate that high expression of CELSR3, GPSM2, or CHEK1 links to unfavorable prognosis of patients with hepatocellular carcinoma.

As mentioned above, mRNA can cross-talk with lncRNA by competitively binding to shared miRNAs ([@B6]). Therefore, potential miRNAs of CELSR3, GPSM2, and CHEK1 and lncRNAs that bind to potential miRNAs were successively predicted. 154 miRNAs of CELSR3, GPSM2, and CHEK1 were first identified using miRNet database. Based on the action mechanism of miRNA on mRNA and putative oncogenic roles of CELSR3, GPSM2, and CHEK1, potential miRNAs should be tumor suppressive miRNAs and should be negatively correlated with CELSR3, GPSM2, or CHEK1. Accordingly, we identified 8 potential pairs (CELSR3-hsa-mir-30a-5p, CELSR3-hsa-mir-4646-3p, CHEK1-hsa-mir-195-5p, CHEK1-hsa-mir-193b-3p, CHEK1-hsa-mir-497-5p, CHEK1-hsa-mir-139-3p, GPSM2-hsa-mir-122-5p, and GPSM2-hsa-mir-378a-5p) by conducting correlation analysis for these mRNA-miRNA interactions in hepatocellular carcinoma. After performing expression analysis, survival analysis and qRT-PCR, three of eight mRNA-miRNA pairs (CHEK1-hsa-mir-195-5p, CHEK1-hsa-mir-497-5p, and GPSM2-hsa-mir-122-5p) were selected for subsequent analysis. Liu et al. ([@B39]) suggested that CHEK1 was a direct target of hsa-mir-195-5p in non-small cell lung cancer; Xie et al. ([@B40]) confirmed that CHEK1 was inversely regulated by hsa-miR-497-5p in hepatocellular carcinoma. In spite of lacking of evidence that has-mir-122-5p directly binds to CHEK1, the inhibitory effect of hsa-mir-122-5p in multiple human cancers has been widely reported ([@B41]--[@B43]). Our current findings together with these reports suggest that CHEK1-hsa-mir-195-5p, CHEK1-hsa-mir-497-5p, and GPSM2-hsa-mir-122-5p may be key pathways in pathogenesis of hepatocellular carcinoma. Next, lncRNAs that bind to hsa-mir-195-5p, hsa-mir-497-5p, or hsa-mir-122-5p were predicted by miRNet and starBase databases. According to ceRNA hypothesis, potential lncRNAs of hsa-mir-195-5p, hsa-mir-497-5p, or hsa-mir-122-5p should act as oncogenic lncRNAs in hepatocellular carcinoma. Among all predicted lncRNAs, nine lncRNAs (SNHG1, SNHG12, LINC00511, HCG18, FGD5-AS1, CERS6-AS1, NUTM2A-AS1, SNHG16, and ASB16-AS1) were significantly upregulated in hepatocellular carcinoma and their upregulation linked to poor prognosis of patients with hepatocellular carcinoma. Most of them have been reported to function as oncogenic lncRNAs in hepatocellular carcinoma. For example, SNHG1 was found to promote liver cancer development through inhibiting p53 expression *via* binding to DNMT1 ([@B44]); Lan et al. ([@B45]) demonstrated that SNHG12 facilitated tumorigenesis and metastasis by targeting miR-199a/b-5p in hepatocellular carcinoma ([@B45]); LINC00511 contributed to cell proliferation and metastasis by modulating miR-424 in hepatocellular carcinoma ([@B46]); SNHG16 was also reported to enhance proliferation, migration and invasion of hepatocellular carcinoma ([@B47]--[@B49]). Besides, a similar mRNA-miRNA-lncRNA analysis for six "known" genes was performed.

By integrating these mRNA-miRNA and miRNA-lncRNA interactions, a potential mRNA-miRNA-lncRNA ceRNA triple sub-network associated with prognosis of hepatocellular carcinoma was constructed. Moreover, ROC curve analysis for these RNAs in the established network revealed that each of them possessed high diagnostic value for hepatocellular carcinoma, further suggesting the key roles of this mRNA-miRNA-lncRNA sub-network in hepatocellular carcinoma. Of course, more corresponding studies need to be launched in the future.

Conclusion {#s5}
==========

In conclusion, using *in silico* analysis and experimental validation, we established a comprehensive mRNA-miRNA-lncRNA triple ceRNA network in hepatocellular carcinoma. Each RNA in this network possesses significant expression difference between hepatocellular carcinoma and normal control and has promising diagnostic and prognostic values for patients with hepatocellular carcinoma. However, these findings need to be further confirmed by more basic experiments and larger-scale clinical trials in the future.
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